Johnson & Johnson has now announced the global phase 3 human trials of its version of the coronavirus vaccine. Compared to others, this vaccine is a one-shot drug that may mark America's first in the medicinal area. The trial is expected to invite at least 60,000 volunteers and may soon allow the company to seek emergency authorization next year. 

COVID-19 vaccine update

As of now, J&J is the fourth vaccine maker in the country that leveled up into late-human stage trials, as reported via Bloomberg.

The company has announced that the human trials had already started to reach volunteers of up to 60,000 people.

If there's one thing that makes their vaccine more effective, the study shows that J&J's vaccine only needs one dose per person to work. 

This means, compared to other pharmaceutical companies, the patient only needs to take a single dose shot of the vaccine to prevent acquiring Coronavirus. 

Once this works and proven effective, this drug could be the very first in America to be a one-shot medicine. 

"We are convinced that the single-dose could be very efficacious," said Johnson & Johnson Chief Scientific Officer Paul Stoffels on a call with the press, citing promising results from earlier research.

Could the one-shot vaccine be effective?

Most of the vaccines (other than COVID vaccines) require more than one dose shot on each human being. Hospitals do an annual test in order for it to be effective. 

So can J&J push through with their original plan? Early studies say yes. 

According to the report, the drug's early experiments were seen effective with non-human primate models (NHP). Six of the NHPs received single immunization with the drug and had shown no detectable virus in the lower respiratory tract despite exposure to SARS-CoV-2. 

Johnson & Johnson is expected to seek emergency authorization from the government early next year. 

ALSO READ: [BREAKING] Coronavirus Is Becoming Stronger: Researchers Discover It's Heat-Resistant and Can Heal Itself

This article is owned by Tech Times

Written by Jamie Pancho 

ⓒ 2024 TECHTIMES.com All rights reserved. Do not reproduce without permission.
Join the Discussion